Ferrous succinate API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Ferrous succinate API 10030-90-7?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Ferrous succinate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ferrous succinate
- Synonyms:
- Iron succinate
- Cas Number:
- 10030-90-7
- DrugBank number:
- DB14489
- Unique Ingredient Identifier:
- 818ZYK7N91
General Description:
Ferrous succinate is a chemical compound identified by the CAS number 10030-90-7. It is known for its distinct pharmacological properties and applications.
Indications:
This drug is primarily indicated for: Used in preventing and treating iron-deficiency anemia. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Absorption:
The absorption characteristics of Ferrous succinate are crucial for its therapeutic efficacy: The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Pharmacodynamics:
Ferrous succinate exerts its therapeutic effects through: The major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia. Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Ferrous succinate functions by: Iron is necessary for the production of hemoglobin. Iron-deficiency can lead to decreased production of hemoglobin and a microcytic, hypochromic anemia. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Categories:
Ferrous succinate is categorized under the following therapeutic classes: Antianemic Preparations, Blood and Blood Forming Organs, Hematinics, Hematologic Agents, Iron Bivalent, Oral Preparations, Iron Compounds, Iron Preparations. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Ferrous succinate is a type of Hematological Agents
Hematological agents, belonging to the pharmaceutical API category, are a vital class of drugs used in the treatment of various blood disorders and hematological conditions. These agents play a crucial role in managing diseases related to the blood and its components, such as red blood cells, white blood cells, platelets, and plasma.
One significant application of hematological agents is in the treatment of anemia, a condition characterized by a low red blood cell count or hemoglobin level. Hematopoietic growth factors, a subclass of hematological agents, stimulate the production of red blood cells and enhance their maturation, thereby addressing anemia.
Another area where hematological agents demonstrate their therapeutic potential is in the treatment of blood cancers, such as leukemia, lymphoma, and multiple myeloma. These agents, including chemotherapy drugs and targeted therapies, help suppress the abnormal growth of cancer cells and restore normal blood cell production.
Hematological agents also find application in managing bleeding disorders, such as hemophilia and thrombocytopenia. They work by promoting blood clotting and preventing excessive bleeding. Additionally, certain hematological agents function as immunosuppressants, playing a crucial role in hematopoietic stem cell transplantation and preventing graft-versus-host disease.
Overall, hematological agents form a vital category within the pharmaceutical API domain, offering targeted treatments for a range of blood disorders and playing a significant role in improving the quality of life for patients with hematological conditions.
